TMB-Guided PD-1 Immunotherapy for Small Cell Lung Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapies, such as those targeting the PD-1/PD-L1 pathway, vary in effectiveness based on patient-specific characteristics, necessitating targeted therapeutic strategies that identify patients likely to respond to anti-cancer agents like anti-PD-1 and anti-CTLA-4 antibodies.
Innovation Solution
Administering anti-PD-1 and/or anti-CTLA-4 antibodies to subjects with small cell lung cancer (SCLC) tumors having a high tumor mutational burden (TMB) status, determined through genomic profiling, to enhance treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-PD-1 and anti-CTLA-4 antibodies are administered to all SCLC patients, then some patients may benefit from immune checkpoint inhibition, but treatment effectiveness varies significantly and many patients do not respond due to heterogeneous tumor characteristics
Solution Approach 1:
The patent applies local quality by tailoring the immunotherapy treatment to specific patient subgroups based on their tumor's TMB status. Instead of uniform treatment, patients are stratified into high-TMB and low-TMB groups, with anti-PD-1/anti-CTLA-4 combination therapy specifically targeted to high-TMB patients who are more likely to respond. This personalized approach improves treatment reliability for the intended population while avoiding ineffective treatments for others.
Solution Approach 2:
The patent utilizes parameter changes by measuring TMB as a biomarker to identify patients whose tumors have specific genetic characteristics (high mutational burden) that make them responsive to immune checkpoint inhibition. The TMB parameter serves as a selector to determine which patients should receive the combination therapy, thereby improving overall treatment effectiveness by applying the therapy only to those whose tumor parameters indicate likely response.
2Reliability
If genomic profiling is performed to identify high TMB tumors before treatment, then treatment efficacy is improved by targeting the right patients, but diagnostic complexity and testing requirements increase
Solution Approach 1:
The patent applies preliminary action by performing genomic profiling and TMB assessment before administering anti-PD-1/anti-CTLA-4 combination therapy. This pre-screening identifies patients with high-TMB tumors who are most likely to benefit from the treatment. By conducting the diagnostic evaluation in advance, the patent ensures that only appropriate candidates receive the complex immunotherapy, thereby improving treatment efficacy while justifying the diagnostic complexity through clear clinical benefit.
Data Source
AI summary
The disclosure provides a method for treating a subject afflicted with a tumor derived from a small cell lung cancer (SCLC) having a high tumor mutational burden (TMB) status comprising administering to the subject a monotherapy comprising an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody. The present disclosure also provides a method for identifying a subject suitable for treatment with an anti-PD-1 antibody or a combination therapy comprising an anti-PD-1 antibody and an anti-CTLA-4 antibody comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.